| Ruling Favors Anthrax-Vaccine Maker Biotechnology company, PharmAthene, won a ruling allowing it to keep a government contract worth about $78 million for developing a new anthrax vaccine. online.wsj.com |
Merck Plays Down J&J Arbitration but Risk Remains EP Vantage submits:Those bosses at Merck & Co (MRK) willing to discuss the issue right now are very much downplaying imminent arbitration with Johnson & Johnson (JNJ) over Remicade and Simponi. Understandable, perhaps, as while consensus is that Merck should win the case on technical grounds, certain other factors make this dispute not quite as cut-and-dry for Merck as it might be for J&J.As EP Vantage has previously reported, J&J has relatively little to lose over the arbitration and potentially a lot to gain (J&J ups the ante in battle for Remicade and Simponi, May 28, 2009). Merck, on the other hand, despite its protestations to the contrary, could see substantial lost value from anything other than an outright win in the dispute - even a compromise settlement could detrimentally impact Merck’s share price.Complete Story » seekingalpha.com |
Bio-Reference Laboratories, Inc. Announces 25% Revenue Growth, 17% Patient Growth, Record Income (Business Wire) ELMWOOD PARK, N.J.----Bio-Reference Laboratories, Inc. announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009. us.rd.yahoo.com |
Drug to Prevent Stroke Is Approved The FDA approved Boehringer Ingelheim's blood-thinning drug Pradaxa to prevent strokes in patients with irregular heart rhythms. online.wsj.com |
LTX-Credence CEO Discusses F1Q2011 Results - Earnings Call Transcript LTX-Credence CorporationF1Q2011 (Qtr 10/31/10) Earnings Conference CallNovember 23, 2010 10:00 AM ETComplete Story » seekingalpha.com |